Andrographolide inhibits ovariectomy-induced bone loss via the suppression of RANKL signaling pathways

International Journal of Molecular Sciences

Volumn 16, Issue 11, 2015, Pages 27470-27481

  Wang, Tao ^a,b   Liu, Qian ^a,b   Zhou, Lin ^c   Yuan, Jin Bo ^c   Lin, Xixi ^a,b   Zeng, Rong ^a,b   Liang, Xiaonan ^b   Zhao, Jinmin ^a,b   Xu, Jiake ^a,b,c  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Andrographolide; Bone loss; Osteoclastogenesis; OVX; RANKL

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ANDROGRAPHOLIDE; CATHEPSIN K; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; TRANSCRIPTION FACTOR NFAT; DITERPENE; MITOGEN ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW OSTEOCLAST CELL; BONE MASS; BONE STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GENE EXPRESSION; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ADVERSE EFFECTS; ANIMAL; DRUG EFFECTS; DRUG THERAPY; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; OSTEOCLAST; OSTEOPOROSIS, POSTMENOPAUSAL; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; BONE RESORPTION; DITERPENES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MICE; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIECTOMY; PHOSPHORYLATION; RANK LIGAND; SIGNAL TRANSDUCTION;

EID: 84947483923     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms161126039     Document Type: Article

References (41)

1. Blume, S.W.; Curtis, J.R. Medical costs of osteoporosis in the elderly medicare population. Osteoporos. Int. 2011, 22, 1835-1844
2. Hadjidakis, D.J.; Androulakis, I.I. Bone remodeling. Ann. N. Y. Acad. Sci. 2006, 1092, 385-396
3. Phan, T.C.; Xu, J.; Zheng, M.H. Interaction between osteoblast and osteoclast: Impact in bone disease. Histol. Histopathol. 2004, 19, 1325-1344
4. Gamble, C.L. Osteoporosis: Making the diagnosis in patients at risk for fracture. Geriatrics 1995, 50, 24-26, 29-30
5. Kassem, M.; Abdallah, B.M.; Saeed, H. Osteoblastic cells: Differentiation and trans-differentiation. Arch. Biochem. Biophys. 2008, 473, 183-187
6. Udagawa, N.; Takahashi, N.; Akatsu, T.; Tanaka, H.; Sasaki, T.; Nishihara, T.; Koga, T.; Martin, T.J.; Suda, T. Origin of osteoclasts: Mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc. Natl. Acad. Sci. USA 1990, 87, 7260-7264
7. Gay, C.V.; Gilman, V.R.; Sugiyama, T. Perspectives on osteoblast and osteoclast function. Poult. Sci. 2000, 79, 1005-1008
8. MacDonald, B.R.; Mundy, G.R.; Clark, S.; Wang, E.A.; Kuehl, T.J.; Stanley, E.R.; Roodman, G.D. Effects of human recombinant CSF-GM and highly purified CSF-1 on the formation of multinucleated cells with osteoclast characteristics in long-term bone marrow cultures. J. Bone Miner. Res. 1986, 1, 227-233
9. Akbar, S. Andrographis paniculata: A review of pharmacological activities and clinical effects. Altern. Med. Rev. 2011, 16, 66-77
10. Zhang, Q.Q.; Ding, Y.; Lei, Y.; Qi, C.L.; He, X.D.; Lan, T.; Li, J.C.; Gong, P.; Yang, X.; Geng, J.G.; et al. Andrographolide suppress tumor growth by inhibiting TLR4/NF-kB signaling activation in insulinoma. Int. J. Biol. Sci. 2014, 10, 404-414
11. Abu-Ghefreh, A.A.; Canatan, H.; Ezeamuzie, C.I. In vitro and in vivo anti-inflammatory effects of andrographolide. Int. Immunopharmacol. 2009, 9, 313-318
12. Shao, Z.J.; Zheng, X.W.; Feng, T.; Huang, J.; Chen, J.;Wu, Y.Y.; Zhou, L.M.; Tu, W.W.; Li, H. Andrographolide exerted its antimicrobial effects by upregulation of human β-defensin-2 induced through p38 MAPK and NF-kB pathway in human lung epithelial cells. Can. J. Physiol. Pharmacol. 2012, 90, 647-653
13. Nguyen, V.S.; Loh, X.Y.; Wijaya, H.; Wang, J.; Lin, Q.; Lam, Y.; Wong, W.S.; Mok, Y.K. Specificity and inhibitory mechanism of andrographolide and its analogues as antiasthma agents on NF-kB p50. J. Nat. Prod. 2015, 78, 208-217
14. Chan, S.J.; Wong, W.S.; Wong, P.T.; Bian, J.S. Neuroprotective effects of andrographolide in a rat model of permanent cerebral ischaemia. Br. J. Pharmacol. 2010, 161, 668-679
15. Al Batran, R.; Al-Bayaty, F.H.; Al-Obaidi, M.M. In-vivo effect of andrographolide on alveolar bone resorption induced by porphyromonas gingivalis and its relation with antioxidant enzymes. Biomed. Res. Int. 2013, 2013, 276329
16. Zhai, Z.J.; Li, H.W.; Liu, G.W.; Qu, X.H.; Tian, B.; Yan, W.; Lin, Z.; Tang, T.T.; Qin, A.; Dai, K.R. Andrographolide suppresses rankl-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo. Br. J. Pharmacol. 2014, 171, 663-675
17. Zhai, Z.; Qu, X.; Yan, W.; Li, H.; Liu, G.; Liu, X.; Tang, T.; Qin, A.; Dai, K. Andrographolide prevents human breast cancer-induced osteoclastic bone loss via attenuated rankl signaling. Breast Cancer Res. Treat. 2014, 144, 33-45
18. Boyce, B.F.; Xiu, Y.; Li, J.; Xing, L.; Yao, Z. NF-KB-mediated regulation of osteoclastogenesis. Endocrinol. Metab. 2015, 30, 35-44
19. Takayanagi, H.; Kim, S.; Koga, T.; Nishina, H.; Isshiki, M.; Yoshida, H.; Saiura, A.; Isobe, M.; Yokochi, T.; Inoue, J.; et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 2002, 3, 889-901
20. Kim, K.; Lee, S.H.; Ha Kim, J.; Choi, Y.; Kim, N. NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol. Endocrinol. 2008, 22, 176-185
21. Matsumoto, M.; Sudo, T.; Saito, T.; Osada, H.; Tsujimoto, M. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-KB ligand (RANKL). J. Biol. Chem. 2000, 275, 31155-31161
22. Hsu, H.; Lacey, D.L.; Dunstan, C.R.; Solovyev, I.; Colombero, A.; Timms, E.; Tan, H.L.; Elliott, G.; Kelley, M.J.; Sarosi, I.; et al. Tumor necrosis factor receptor family member rank mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA 1999, 96, 3540-3545
23. Weitzmann, M.N.; Pacifici, R. Estrogen deficiency and bone loss: An inflammatory tale. J. Clin. Investig. 2006, 116, 1186-1194
24. Boyce, B.F.; Rosenberg, E.; de Papp, A.E.; Duong, L.T. The osteoclast, bone remodelling and treatment of metabolic bone disease. Eur. J. Clin. Investig. 2012, 42, 1332-1341
25. Ang, E.; Liu, Q.; Qi, M.; Liu, H.G.; Yang, X.; Chen, H.; Zheng, M.H.; Xu, J. Mangiferin attenuates osteoclastogenesis, bone resorption, and rankl-induced activation of NF-KB and ERK. J. Cell. Biochem. 2011, 112, 89-97
26. Kim, W.K.; Ke, K.; Sul, O.J.; Kim, H.J.; Kim, S.H.; Lee, M.H.; Kim, H.J.; Kim, S.Y.; Chung, H.T.; Choi, H.S. Curcumin protects against ovariectomy-induced bone loss and decreases osteoclastogenesis. J. Cell. Biochem. 2011, 112, 3159-3166
27. Li, F.; Sun, X.; Ma, J.; Ma, X.; Zhao, B.; Zhang, Y.; Tian, P.; Li, Y.; Han, Z. Naringin prevents ovariectomy-induced osteoporosis and promotes osteoclasts apoptosis through the mitochondria-mediated apoptosis pathway. Biochem. Biophys. Res. Commun. 2014, 452, 629-635
28. Eriksen, E.F.; Hodgson, S.F.; Eastell, R.; Cedel, S.L.; O’Fallon, W.M.; Riggs, B.L. Cancellous bone remodeling in type I (postmenopausal) osteoporosis: Quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels. J. Bone Miner. Res. 1990, 5, 311-319
29. Yavropoulou, M.P.; Yovos, J.G. Osteoclastogenesis-Current knowledge and future perspectives. J. Musculoskelet. Neuronal Interact. 2008, 8, 204-216.
30. Feng, X.; McDonald, J.M. Disorders of bone remodeling. Annu. Rev. Pathol. 2011, 6, 121-145
31. Iotsova, V.; Caamano, J.; Loy, J.; Yang, Y.; Lewin, A.; Bravo, R. Osteopetrosis in mice lacking NF-kB1 and NF-kB2. Nat. Med. 1997, 3, 1285-1289
32. Asagiri, M.; Sato, K.; Usami, T.; Ochi, S.; Nishina, H.; Yoshida, H.; Morita, I.; Wagner, E.F.; Mak, T.W.; Serfling, E.; et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J. Exp. Med. 2005, 202, 1261-1269
33. Franzoso, G.; Carlson, L.; Xing, L.; Poljak, L.; Shores, E.W.; Brown, K.D.; Leonardi, A.; Tran, T.; Boyce, B.F.; Siebenlist, U. Requirement for NF-KB in osteoclast and B-cell development. Genes Dev. 1997, 11, 3482-3496
34. Xia, Y.F.; Ye, B.Q.; Li, Y.D.; Wang, J.G.; He, X.J.; Lin, X.; Yao, X.; Ma, D.; Slungaard, A.; Hebbel, R.P.; et al. Andrographolide attenuates inflammation by inhibition of NF-KB activation through covalent modification of reduced cysteine 62 of p50. J. Immunol. 2004, 173, 4207-4217
35. Zhao, Q.; Wang, X.; Liu, Y.; He, A.; Jia, R. Nfatc1: Functions in osteoclasts. Int. J. Biochem. Cell Biol. 2010, 42, 576-579
36. Aliprantis, A.O.; Ueki, Y.; Sulyanto, R.; Park, A.; Sigrist, K.S.; Sharma, S.M.; Ostrowski, M.C.; Olsen, B.R.; Glimcher, L.H. NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J. Clin. Investig. 2008, 118, 3775-3789
37. Pacifici, R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J. Bone Miner. Res. 1996, 11, 1043-1051
38. Cenci, S.; Weitzmann, M.N.; Roggia, C.; Namba, N.; Novack, D.; Woodring, J.; Pacifici, R. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-K. J. Clin. Investig. 2000, 106, 1229-1237
39. Xu, J.; Tan, J.W.; Huang, L.; Gao, X.H.; Laird, R.; Liu, D.; Wysocki, S.; Zheng, M.H. Cloning, sequencing, and functional characterization of the rat homologue of receptor activator of NF-kB ligand. J. Bone Miner. Res. 2000, 15, 2178-2186
40. Wang, C.; Steer, J.H.; Joyce, D.A.; Yip, K.H.; Zheng, M.H.; Xu, J. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing rankl-induced NF-kB activation. J. Bone Miner. Res. 2003, 18, 2159-2168
41. van der Kraan, A.G.; Chai, R.C.; Singh, P.P.; Lang, B.J.; Xu, J.; Gillespie, M.T.; Price, J.T.; Quinn, J.M. Hsp90 inhibitors enhance differentiation and MITF (microphthalmia transcription factor) activity in osteoclast progenitors. Biochem. J. 2013, 451, 235-244